APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rotavirus Infections Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Rotavirus Infections Drug Industry Research Report 2026

Report ID 174033570522 December 2025115 pages

Choose your research edition.

Industry ResearchRotavirus Infections Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Rotavirus Infections Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Rotavirus Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rotavirus Infections Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Rotavirus Infections Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Rotavirus Infections Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Rotavirus Infections Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Rotavirus Infections Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Rotavirus Infections Drug include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Rotavirus Infections Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Rotavirus Infections Drug Market by Company

Wuhan Institute of Biological Products Co Ltd

Beijing Minhai Biotechnology Co Ltd

UMN Pharma Inc

Serum Institute of India Ltd

Nanotherapeutics Inc

Medicago Inc

Curevac AG

Biological E Ltd

Bharat Biotech International Ltd

Rotavirus Infections Drug Segment by Type

UMN-2001

RV-625

RV-3BB

Rotavac-5C

Others

Rotavirus Infections Drug Segment by Application

Clinic

Hospital

Others

Rotavirus Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Rotavirus Infections Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Rotavirus Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Rotavirus Infections Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Rotavirus Infections Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Rotavirus Infections Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Rotavirus Infections Drug Revenue of Manufacturers (2021-2026) Table 9. Global Rotavirus Infections Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Rotavirus Infections Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Rotavirus Infections Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Rotavirus Infections Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Rotavirus Infections Drug, Product Type & Application Table 14. Global Rotavirus Infections Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Rotavirus Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Wuhan Institute of Biological Products Co Ltd Company Information Table 19. Wuhan Institute of Biological Products Co Ltd Business Overview Table 20. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio Table 22. Wuhan Institute of Biological Products Co Ltd Recent Developments Table 23. Beijing Minhai Biotechnology Co Ltd Company Information Table 24. Beijing Minhai Biotechnology Co Ltd Business Overview Table 25. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio Table 27. Beijing Minhai Biotechnology Co Ltd Recent Developments Table 28. UMN Pharma Inc Company Information Table 29. UMN Pharma Inc Business Overview Table 30. UMN Pharma Inc Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. UMN Pharma Inc Rotavirus Infections Drug Product Portfolio Table 32. UMN Pharma Inc Recent Developments Table 33. Serum Institute of India Ltd Company Information Table 34. Serum Institute of India Ltd Business Overview Table 35. Serum Institute of India Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio Table 37. Serum Institute of India Ltd Recent Developments Table 38. Nanotherapeutics Inc Company Information Table 39. Nanotherapeutics Inc Business Overview Table 40. Nanotherapeutics Inc Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio Table 42. Nanotherapeutics Inc Recent Developments Table 43. Medicago Inc Company Information Table 44. Medicago Inc Business Overview Table 45. Medicago Inc Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Medicago Inc Rotavirus Infections Drug Product Portfolio Table 47. Medicago Inc Recent Developments Table 48. Curevac AG Company Information Table 49. Curevac AG Business Overview Table 50. Curevac AG Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Curevac AG Rotavirus Infections Drug Product Portfolio Table 52. Curevac AG Recent Developments Table 53. Biological E Ltd Company Information Table 54. Biological E Ltd Business Overview Table 55. Biological E Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Biological E Ltd Rotavirus Infections Drug Product Portfolio Table 57. Biological E Ltd Recent Developments Table 58. Bharat Biotech International Ltd Company Information Table 59. Bharat Biotech International Ltd Business Overview Table 60. Bharat Biotech International Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio Table 62. Bharat Biotech International Ltd Recent Developments Table 63. Global Rotavirus Infections Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 64. Global Rotavirus Infections Drug Sales by Region (2021-2026) & (k units) Table 65. Global Rotavirus Infections Drug Sales Market Share by Region (2021-2026) Table 66. Global Rotavirus Infections Drug Sales by Region (2027-2032) & (k units) Table 67. Global Rotavirus Infections Drug Sales Market Share by Region (2027-2032) Table 68. Global Rotavirus Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Rotavirus Infections Drug Revenue Market Share by Region (2021-2026) Table 70. Global Rotavirus Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Rotavirus Infections Drug Revenue Market Share by Region (2027-2032) Table 72. North America Rotavirus Infections Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. North America Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 74. North America Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 75. North America Rotavirus Infections Drug Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Rotavirus Infections Drug Revenue by Country (2027-2032) & (US$ Million) Table 77. Europe Rotavirus Infections Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Europe Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 79. Europe Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 80. Europe Rotavirus Infections Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Rotavirus Infections Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Asia Pacific Rotavirus Infections Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Asia Pacific Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 84. Asia Pacific Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 85. Asia Pacific Rotavirus Infections Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. Asia Pacific Rotavirus Infections Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. South America Rotavirus Infections Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. South America Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 89. South America Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 90. South America Rotavirus Infections Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. South America Rotavirus Infections Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Middle East and Africa Rotavirus Infections Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Middle East and Africa Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 94. Middle East and Africa Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 95. Middle East and Africa Rotavirus Infections Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Middle East and Africa Rotavirus Infections Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Global Rotavirus Infections Drug Sales by Type (2021-2026) & (k units) Table 98. Global Rotavirus Infections Drug Sales by Type (2027-2032) & (k units) Table 99. Global Rotavirus Infections Drug Sales Market Share by Type (2021-2026) Table 100. Global Rotavirus Infections Drug Sales Market Share by Type (2027-2032) Table 101. Global Rotavirus Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 102. Global Rotavirus Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 103. Global Rotavirus Infections Drug Revenue Market Share by Type (2021-2026) Table 104. Global Rotavirus Infections Drug Revenue Market Share by Type (2027-2032) Table 105. Global Rotavirus Infections Drug Price by Type (2021-2026) & (US$/unit) Table 106. Global Rotavirus Infections Drug Price by Type (2027-2032) & (US$/unit) Table 107. Global Rotavirus Infections Drug Sales by Application (2021-2026) & (k units) Table 108. Global Rotavirus Infections Drug Sales by Application (2027-2032) & (k units) Table 109. Global Rotavirus Infections Drug Sales Market Share by Application (2021-2026) Table 110. Global Rotavirus Infections Drug Sales Market Share by Application (2027-2032) Table 111. Global Rotavirus Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. Global Rotavirus Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. Global Rotavirus Infections Drug Revenue Market Share by Application (2021-2026) Table 114. Global Rotavirus Infections Drug Revenue Market Share by Application (2027-2032) Table 115. Global Rotavirus Infections Drug Price by Application (2021-2026) & (US$/unit) Table 116. Global Rotavirus Infections Drug Price by Application (2027-2032) & (US$/unit) Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Rotavirus Infections Drug Distributors List Table 120. Rotavirus Infections Drug Customers List Table 121. Rotavirus Infections Drug Industry Trends Table 122. Rotavirus Infections Drug Industry Drivers Table 123. Rotavirus Infections Drug Industry Restraints Table 124. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Rotavirus Infections Drug Product Image Figure 5. Global Rotavirus Infections Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Rotavirus Infections Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Rotavirus Infections Drug Sales (2021-2032) & (k units) Figure 8. Global Rotavirus Infections Drug Average Price (US$/unit) & (2021-2032) Figure 9. UMN-2001 Product Image Figure 10. RV-625 Product Image Figure 11. RV-3BB Product Image Figure 12. Rotavac-5C Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Others Product Image Figure 17. Global Rotavirus Infections Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Rotavirus Infections Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Rotavirus Infections Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Rotavirus Infections Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Rotavirus Infections Drug Sales by Region in 2025 Figure 23. Global Rotavirus Infections Drug Revenue by Region in 2025 Figure 24. North America Rotavirus Infections Drug Market Size by Country in 2025 Figure 25. North America Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 26. North America Rotavirus Infections Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Rotavirus Infections Drug Market Size by Country in 2025 Figure 31. Europe Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Rotavirus Infections Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Rotavirus Infections Drug Market Size by Country in 2025 Figure 44. Asia Pacific Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Rotavirus Infections Drug Revenue Market Share by Country (2021-2032) Figure 46. China Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Rotavirus Infections Drug Market Size by Country in 2025 Figure 55. South America Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 56. South America Rotavirus Infections Drug Revenue Market Share by Country (2021-2032) Figure 57. Brazil Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Rotavirus Infections Drug Market Size by Country in 2025 Figure 61. Middle East and Africa Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Rotavirus Infections Drug Revenue Market Share by Country (2021-2032) Figure 63. Egypt Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Rotavirus Infections Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Rotavirus Infections Drug Sales Market Share by Type (2021-2032) Figure 69. Global Rotavirus Infections Drug Revenue Market Share by Type (2021-2032) Figure 70. Global Rotavirus Infections Drug Price (US$/unit) by Type (2021-2032) Figure 71. Global Rotavirus Infections Drug Sales Market Share by Application (2021-2032) Figure 72. Global Rotavirus Infections Drug Revenue Market Share by Application (2021-2032) Figure 73. Global Rotavirus Infections Drug Price (US$/unit) by Application (2021-2032) Figure 74. Rotavirus Infections Drug Value Chain Figure 75. Rotavirus Infections Drug Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Rotavirus Infections Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • UMN-2001
  • RV-625
  • RV-3BB
  • Rotavac-5C
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Wuhan Institute of Biological Products Co Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • UMN Pharma Inc
  • Serum Institute of India Ltd
  • Nanotherapeutics Inc
  • Medicago Inc
  • Curevac AG
  • Biological E Ltd
  • Bharat Biotech International Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Rotavirus Infections Drug Market Size (2021-2032)
  4. 2.2.2 Global Rotavirus Infections Drug Sales (2021-2032)
  5. 2.2.3 Global Rotavirus Infections Drug Market Average Price (2021-2032)
  6. 2.3 Rotavirus Infections Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 UMN-2001
  9. 2.3.3 RV-625
  10. 2.3.4 RV-3BB
  11. 2.3.5 Rotavac-5C
  12. 2.3.6 Others
  13. 2.4 Rotavirus Infections Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Rotavirus Infections Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Rotavirus Infections Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Rotavirus Infections Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Rotavirus Infections Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Rotavirus Infections Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Rotavirus Infections Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Rotavirus Infections Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Rotavirus Infections Drug, Established Date
  9. 3.9 Global Rotavirus Infections Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Wuhan Institute of Biological Products Co Ltd
  2. 4.1.1 Wuhan Institute of Biological Products Co Ltd Company Information
  3. 4.1.2 Wuhan Institute of Biological Products Co Ltd Business Overview
  4. 4.1.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
  6. 4.1.5 Wuhan Institute of Biological Products Co Ltd Recent Developments
  7. 4.2 Beijing Minhai Biotechnology Co Ltd
  8. 4.2.1 Beijing Minhai Biotechnology Co Ltd Company Information
  9. 4.2.2 Beijing Minhai Biotechnology Co Ltd Business Overview
  10. 4.2.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
  12. 4.2.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
  13. 4.3 UMN Pharma Inc
  14. 4.3.1 UMN Pharma Inc Company Information
  15. 4.3.2 UMN Pharma Inc Business Overview
  16. 4.3.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
  18. 4.3.5 UMN Pharma Inc Recent Developments
  19. 4.4 Serum Institute of India Ltd
  20. 4.4.1 Serum Institute of India Ltd Company Information
  21. 4.4.2 Serum Institute of India Ltd Business Overview
  22. 4.4.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
  24. 4.4.5 Serum Institute of India Ltd Recent Developments
  25. 4.5 Nanotherapeutics Inc
  26. 4.5.1 Nanotherapeutics Inc Company Information
  27. 4.5.2 Nanotherapeutics Inc Business Overview
  28. 4.5.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
  30. 4.5.5 Nanotherapeutics Inc Recent Developments
  31. 4.6 Medicago Inc
  32. 4.6.1 Medicago Inc Company Information
  33. 4.6.2 Medicago Inc Business Overview
  34. 4.6.3 Medicago Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Medicago Inc Rotavirus Infections Drug Product Portfolio
  36. 4.6.5 Medicago Inc Recent Developments
  37. 4.7 Curevac AG
  38. 4.7.1 Curevac AG Company Information
  39. 4.7.2 Curevac AG Business Overview
  40. 4.7.3 Curevac AG Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Curevac AG Rotavirus Infections Drug Product Portfolio
  42. 4.7.5 Curevac AG Recent Developments
  43. 4.8 Biological E Ltd
  44. 4.8.1 Biological E Ltd Company Information
  45. 4.8.2 Biological E Ltd Business Overview
  46. 4.8.3 Biological E Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Biological E Ltd Rotavirus Infections Drug Product Portfolio
  48. 4.8.5 Biological E Ltd Recent Developments
  49. 4.9 Bharat Biotech International Ltd
  50. 4.9.1 Bharat Biotech International Ltd Company Information
  51. 4.9.2 Bharat Biotech International Ltd Business Overview
  52. 4.9.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
  54. 4.9.5 Bharat Biotech International Ltd Recent Developments
5 Global Rotavirus Infections Drug Market Scenario by Region
  1. 5.1 Global Rotavirus Infections Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Rotavirus Infections Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Rotavirus Infections Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Rotavirus Infections Drug Sales by Region: 2027-2032
  5. 5.3 Global Rotavirus Infections Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Rotavirus Infections Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Rotavirus Infections Drug Revenue by Region: 2027-2032
  8. 5.4 North America Rotavirus Infections Drug Market Facts & Figures by Country
  9. 5.4.1 North America Rotavirus Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Rotavirus Infections Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Rotavirus Infections Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Rotavirus Infections Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Rotavirus Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Rotavirus Infections Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Rotavirus Infections Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Rotavirus Infections Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Rotavirus Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Rotavirus Infections Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Rotavirus Infections Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Rotavirus Infections Drug Market Facts & Figures by Country
  41. 5.7.1 South America Rotavirus Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Rotavirus Infections Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Rotavirus Infections Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Rotavirus Infections Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Rotavirus Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Rotavirus Infections Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Rotavirus Infections Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Rotavirus Infections Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Rotavirus Infections Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Rotavirus Infections Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Rotavirus Infections Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Rotavirus Infections Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Rotavirus Infections Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Rotavirus Infections Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Rotavirus Infections Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Rotavirus Infections Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Rotavirus Infections Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Rotavirus Infections Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Rotavirus Infections Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Rotavirus Infections Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Rotavirus Infections Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Rotavirus Infections Drug Value Chain Analysis
  2. 8.1.1 Rotavirus Infections Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Rotavirus Infections Drug Production Mode & Process
  5. 8.2 Rotavirus Infections Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Rotavirus Infections Drug Distributors
  8. 8.2.3 Rotavirus Infections Drug Customers
9 Global Rotavirus Infections Drug Analyzing Market Dynamics
  1. 9.1 Rotavirus Infections Drug Industry Trends
  2. 9.2 Rotavirus Infections Drug Industry Drivers
  3. 9.3 Rotavirus Infections Drug Industry Opportunities and Challenges
  4. 9.4 Rotavirus Infections Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst